Sanara MedTech Inc. Announces Chief Executive Officer Transition
Sanara MedTech (NASDAQ: SMTI) announced a significant leadership transition, appointing Seth Yon as President, CEO, and Board Director, effective September 15, 2025. Yon, currently serving as President and Chief Commercial Officer, will succeed Ron Nixon, who will continue as Executive Chairman.
Under Yon's various leadership roles since joining in 2018, Sanara achieved remarkable 53% compound annual net revenue growth over the past three fiscal years. His progression through the company included positions as Director of Sales, National Sales Director, VP of Commercial, and President of Commercial.
The appointment represents the culmination of a strategic initiative to strengthen senior leadership and position Sanara for future growth in surgical, chronic wound, and skin markets. Yon brings 27 years of industry experience, including previous roles at Iroquois Industrial Group, GreenerGrads, and Jostens, Inc.
Sanara MedTech (NASDAQ: SMTI) ha annunciato un rilevante avvicendamento ai vertici: Seth Yon è stato nominato Presidente, CEO e membro del Consiglio di Amministrazione, con decorrenza 15 settembre 2025. Yon, attualmente Presidente e Chief Commercial Officer, succederà a Ron Nixon, che resterà Executive Chairman.
Da quando è entrato in azienda nel 2018, Yon ha ricoperto diversi ruoli di leadership, contribuendo a una consistente crescita annua composta del 53% dei ricavi netti negli ultimi tre esercizi. Il suo percorso in Sanara comprende incarichi come Director of Sales, National Sales Director, VP of Commercial e President of Commercial.
La nomina completa una strategia mirata a rafforzare la leadership aziendale e a preparare Sanara per la crescita nei mercati della chirurgia, delle ferite croniche e della cura della pelle. Yon porta con sé 27 anni di esperienza nel settore, con precedenti ruoli in Iroquois Industrial Group, GreenerGrads e Jostens, Inc.
Sanara MedTech (NASDAQ: SMTI) anunció un importante cambio en su dirección: Seth Yon ha sido nombrado Presidente, CEO y miembro del Consejo, con efecto desde el 15 de septiembre de 2025. Yon, que actualmente se desempeña como Presidente y Chief Commercial Officer, sucederá a Ron Nixon, quien permanecerá como Executive Chairman.
Desde que se incorporó en 2018, Yon ha ocupado diversos puestos de liderazgo y ha impulsado un notable crecimiento anual compuesto del 53% en los ingresos netos durante los últimos tres ejercicios. Su trayectoria en la compañía incluye cargos como Director de Ventas, National Sales Director, VP of Commercial y President of Commercial.
El nombramiento es el resultado de una iniciativa estratégica para reforzar la alta dirección y posicionar a Sanara para el crecimiento futuro en los mercados de cirugía, heridas crónicas y cuidado de la piel. Yon aporta 27 años de experiencia en la industria, con anteriores posiciones en Iroquois Industrial Group, GreenerGrads y Jostens, Inc.
Sanara MedTech (NASDAQ: SMTI)는 주요 경영진 변경을 발표하며 Seth Yon을 2025년 9월 15일자부로 회장 겸 CEO 및 이사로 선임했습니다. 현재 회장 겸 Chief Commercial Officer인 Yon은 Ron Nixon의 뒤를 잇게 되며 Nixon은 Executive Chairman으로 남습니다.
Yon은 2018년 입사 이후 여러 리더십 직책을 역임하며 최근 3개 회계연도 동안 순매출 연평균 복합 성장률 53%라는 눈에 띄는 성과를 달성하는 데 기여했습니다. 그가 회사에서 거쳐온 직책에는 Director of Sales, National Sales Director, VP of Commercial, President of Commercial 등이 포함됩니다.
이번 임명은 수술, 만성 상처 및 피부 시장에서의 향후 성장을 위해 고위 경영진을 강화하려는 전략적 노력의 완성입니다. Yon은 Iroquois Industrial Group, GreenerGrads, Jostens, Inc. 등에서의 경력을 포함해 27년의 업계 경험을 보유하고 있습니다.
Sanara MedTech (NASDAQ: SMTI) a annoncé un important changement de direction : Seth Yon a été nommé Président, CEO et administrateur du conseil, à compter du 15 septembre 2025. Yon, actuellement President et Chief Commercial Officer, succédera à Ron Nixon, qui restera Executive Chairman.
Depuis son arrivée en 2018, Yon a occupé plusieurs postes de direction et a contribué à une remarquable croissance annuelle composée des revenus nets de 53% au cours des trois derniers exercices. Son parcours au sein de l'entreprise inclut les fonctions de Director of Sales, National Sales Director, VP of Commercial et President of Commercial.
Cette nomination concrétise une initiative stratégique visant à renforcer l'équipe dirigeante et à positionner Sanara pour la croissance future sur les marchés de la chirurgie, des plaies chroniques et des soins de la peau. Yon apporte 27 ans d'expérience dans le secteur, avec des expériences précédentes chez Iroquois Industrial Group, GreenerGrads et Jostens, Inc.
Sanara MedTech (NASDAQ: SMTI) gab eine bedeutende Führungsänderung bekannt: Seth Yon wurde zum Präsidenten, CEO und Vorstandsmitglied ernannt, wirksam ab dem 15. September 2025. Yon, derzeit President und Chief Commercial Officer, tritt die Nachfolge von Ron Nixon an, der weiterhin als Executive Chairman tätig sein wird.
Seit seinem Eintritt 2018 hat Yon in verschiedenen Führungsfunktionen zum bemerkenswerten jährlichen durchschnittlichen Nettoumsatzwachstum von 53% in den letzten drei Geschäftsjahren beigetragen. Seine Stationen im Unternehmen umfassen Director of Sales, National Sales Director, VP of Commercial und President of Commercial.
Die Bestellung ist der Abschluss einer strategischen Initiative zur Stärkung der Unternehmensleitung und zur Positionierung von Sanara für künftiges Wachstum in den Bereichen Chirurgie, chronische Wunden und Hautmärkte. Yon bringt 27 Jahre Branchenerfahrung mit, unter anderem von Iroquois Industrial Group, GreenerGrads und Jostens, Inc.
- Achieved 53% compound annual net revenue growth over three fiscal years
- Structured leadership transition maintaining continuity with Executive Chairman
- Appointment represents culmination of long-term leadership development strategy
- New CEO brings 27 years of industry experience and proven track record of growth
- None.
Insights
Sanara MedTech's promotion of Seth Yon to CEO reflects strong internal succession planning and positions the company for continued revenue growth.
Seth Yon's appointment as CEO of Sanara MedTech represents a well-orchestrated leadership transition that has been strategically planned over time. Under Yon's commercial leadership, the company has achieved impressive
The transition demonstrates healthy organizational development, with Ron Nixon remaining as Executive Chairman to ensure continuity while focusing on strategic initiatives across both the Sanara Surgical and Tissue Health Plus segments. This collaborative leadership approach minimizes disruption risks typically associated with CEO changes.
Yon brings valuable institutional knowledge from his progressive seven-year journey through the company, having started as Director of Sales and systematically advancing through increasingly responsible positions. His deep understanding of the company's commercial operations, having personally helped build and scale the sales organization, should enable a smooth transition.
This succession appears to be part of a deliberate long-term strategy rather than a reactive change, suggesting organizational stability. Yon's combined commercial background at Sanara and prior leadership experience at Iroquois Industrial Group positions him well to oversee both revenue growth and operational execution across Sanara's multiple market segments.
The announcement reinforces Sanara's focus on substantial market opportunities, with Yon acknowledging the company remains in "early stages" with "significant greenfield opportunity" to penetrate large patient populations – signaling a continued growth-oriented strategy under his leadership.
Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman
FORT WORTH, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that Seth Yon, Sanara’s President and Chief Commercial Officer, has been appointed to the position of President and Chief Executive Officer and will join the Board of Directors, effective September 15, 2025. Mr. Yon will succeed Ron Nixon, who will continue to serve as Executive Chairman.
“I am very pleased to announce that the Board of Directors has voted unanimously to appoint Seth to the role of President and Chief Executive Officer,” stated Ron Nixon. “Over the past seven years, Seth has proven himself to be a strategic, capable and well-regarded leader serving Sanara in senior-level management positions of increasing responsibility. During his tenures as our Vice President of Commercial, President of Commercial and, most recently, as President and Chief Commercial Officer, Sanara achieved annual net revenue growth of
Mr. Nixon continued: “Today’s announcement is the culmination of a longer-term initiative to develop and structure our senior leadership team, with the goal of positioning Sanara for future success in the markets we serve. Seth has been immersed in all key aspects of our business and is well-versed in the initiatives we are pursuing across our organization. He has cultivated an impressive senior leadership team in our Sanara Surgical segment, headed by our Vice Presidents of Sales and Market Development, who will continue to inform, support and execute our commercial strategy. As Executive Chairman, I will remain focused on the current initiatives we are pursuing in our Sanara Surgical and Tissue Health Plus segments, along with other key aspects of our strategy, to support Seth in his new role. My fellow directors and I believe he is the ideal CEO candidate to lead the next phase of Sanara’s growth and value creation, and we look forward to this new chapter under his strategic leadership.”
“Working alongside Sanara’s talented team to improve patient outcomes and deliver value to the healthcare system has proven to be one of the greatest highlights of my 27-year career,” stated Seth Yon. “In spite of the important progress we have made together, I believe Sanara remains in the early stages of its journey as an organization, with a significant greenfield opportunity ahead as we continue to penetrate the large patient populations that our treatments address. I am honored to assume the CEO role and excited by the prospect of leading the Sanara team though this important stage as an organization, for the benefit of all our stakeholders.”
Seth Yon joined Sanara in March 2018 as Director of Sales, Wound Care, and one of the first Regional Sales Managers, playing a pivotal role in establishing the Company’s early commercial operations and markets. Mr. Yon was promoted to National Sales Director in January 2020, and later Vice President of Commercial beginning January 2022, where he oversaw strong growth and execution in Sanara Surgical segment, while developing Sanara’s sales processes, performance metrics and training practices. He was promoted to President of Commercial in August 2023 and has served as Sanara’s President and Chief Commercial Officer since April 2025, where he was responsible for the Company’s commercial strategy and execution across all U.S. markets.
Prior to joining Sanara, Mr. Yon served as Vice President of Sales and Marketing for Iroquois Industrial Group (“Iroquois”), from 2015 to 2018. Prior to joining Iroquois, Mr. Yon founded and led the development of GreenerGrads from 2011 to 2014. Mr. Yon began his career as a Sales Representative and Independent Territory Manager at Jostens, Inc., where he worked from 1999 to 2011. He holds a B.A. from Grand Valley State University.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets. The Company markets, distributes and develops surgical, wound and skin products for use by physicians and clinicians in hospitals, clinics and all post-acute care. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen®, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN™ Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, TEXAGEN® Amniotic Membrane Allograft, and BIASURGE® Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS® Antimicrobial Wound Gel, and BIAKŌS® Antimicrobial Skin and Wound Irrigation Solution. Sanara's pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. For more information, please visit SanaraMedTech.com.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s business strategy and mission, future opportunities for expansion, the development of new products, the timing of commercialization of the Company’s products and the regulatory approval process. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, the Company’s ability to validate and optimize the Tissue Health Plus (“THP”) technology platform, the Company’s ability to build out its executive team, the Company’s ability to identify and effectively utilize the net proceeds of the CRG Term Loan Agreement to support the Company’s growth initiatives, the extent of product demand, market and customer acceptance, including acceptance of the THP technology platform, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Relations Contact:
Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com
FAQ
Who is the new CEO of Sanara MedTech (SMTI)?
What is Sanara MedTech's (SMTI) revenue growth under Seth Yon's leadership?
What is Ron Nixon's new role at Sanara MedTech (SMTI)?
What is Seth Yon's background before joining Sanara MedTech (SMTI)?
What markets does Sanara MedTech (SMTI) operate in?
